Stemina Biomarker Discovery is developing a cardiotoxicity assay based on human heart cells that screens compounds for the potential to cause a variety of types of cardiotoxicity. We are currently seeking collaborators to provide test compounds with known cardiotoxic effects for assay evaluation.
Benefits to Collaboration are:
- Early access to assay evaluation data and Stemina experts
- Input into defining endpoints of interest for cardiotoxicity assessment
Pilot studies conducted with a set of 24 pharmaceutical agents of known cardiotoxicity demonstrated our ability to separate cardiotoxins from non-toxins using a metabolomics-based assay with high accuracy. Ongoing experiments will expand upon the pilot study, using untargeted metabolomics of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMS) exposed to a broad trainin set of 60 compounds consisting of functional, structural, and general cardiotoxicants, as well as compounds that are known not to have cardiotoxic effects.
These technologies will be used to discover human, endogenous metabolite biomarkers, which predict general cardiotoxicity as well as the specific type of cardiotoxicity (e.g., functional, structural).
For more information, please read our Online Brochure.
Cardioqp uses iCell® cardiomyocytes: Video of beating iCell® Cardiomyocytes courtesy of Cellular Dynamics International, a FUJIFILM company